Penwest Pharmaceuticals have initiated a Phase IIa Clinical Trial for A0001 due to commence in December. Screening of prospective patients is underway. The study will be conducted at the Children’s Hospital of Philadelphia.
The Phase IIa Clinical Trial is a double-blind, randomised, placebo-controlled trial that includes high and low doses of A0001 and a placebo. The objective of the study will be to investigate if A0001 has a discernable impact on various functional, biochemical and subject/clinical-rated scales relevant in the treatment of FA.
Penwest intends to enrol 42 patients and they will be dosed for 28 days. For more details about A0001 or Penwest Pharmaceuticals, read their press release here.